Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Feb;108(1):24-9.
doi: 10.1016/j.jnma.2015.12.004.

A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment

Affiliations
Meta-Analysis

A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment

Julius Wilder et al. J Natl Med Assoc. 2016 Feb.

Abstract

The African American/Black population in the United States (US) is disproportionately affected by hepatitis C virus (HCV) and has lower response rates to current treatments. This analysis evaluates the participation of African American/Blacks in North American and European HCV clinical trials. The data source for this analysis was the PubMed database. Randomized controlled clinical trials (RCT) on HCV treatment with interferon 2a or 2b between January 2000 and December 2011 were reviewed. Inclusion criteria included English language and participants 18 years or older with chronic HCV. Exclusion criteria included non-randomized trials, case reports, cohort studies, ethnic specific studies, or studies not using interferon-alfa or PEG-interferon. Of the 588 trials identified, 314 (53.4%) fit inclusion criteria. The main outcome was the rate of African American/ Black participation in North American HCV clinical trials. A meta-analysis comparing the expected and observed rates was performed. Of the RCT's that met search criteria, 123 (39.2%) reported race. Clinical trials in North America were more likely to report racial data than European trials. Racial reporting increased over time. There was a statistically significant difference among the expected and observed participation of African Americans in HCV clinical trials in North America based on the prevalence of this disease within the population. The burden of HCV among African Americans in North America is not reflected in those clinical trials designed to treat HCV. Research on minority participation in clinical trials and how to increase minority participation in clinical trials is needed.

Keywords: African American/Black; Clinical Trial; Hepatitis C.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Results of PubMed literature search.
Figure 2
Figure 2
Reporting of race in RCT's conducted partially and only in North America and Europe
Figure 3
Figure 3
Participation of black and white patients in RCT's conducted partially and only in North America
Figure 4
Figure 4
Rate of African American/Black Participation in North American Hepatitis C Clinical Trials from 2000–2011

References

    1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. The Lancet infectious diseases. 2005 Sep;5(9):558–567. - PubMed
    1. Lavanchy D. The global burden of hepatitis C. Liver international: official journal of the International Association for the Study of the Liver. 2009 Feb;29(Suppl 1):74–81. - PubMed
    1. Centers for Disease Control and Prevention. Hepatitis C Information for Health Professionals. Centers for Disease Control and Prevention; 2008. http://www.cdc.gov/hepatitis/hcv/
    1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Annals of internal medicine. 2006 Jun 16;144(10):705–714. - PubMed
    1. NIH consensus statement on management of hepatitis C: 2002. Consensus Development Conference presented at NIH consensus and state-of-the-science statements; Jul, 2002. - PubMed

Publication types